# ASTRIDE (NCT05468489)

> To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05468489
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Shanghai Henlius Biotech
- Conditions: Extensive Stage Small Cell Lung Cancer
- Interventions: Serplulimab + chemotherapy (carboplatin-etoposide); Atezolizumab + chemotherapy (carboplatin-etoposide)
- Enrollment: 200
- Primary outcome: OS

## Indexed commentary on ASTRIDE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 13

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=astride-nct05468489

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05468489", "email": "<work email>"}; the inbox owner confirms by the emailed link.